Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MYC mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MYC mutation	Colorectal Cancer	MYC mutation	Colorectal Cancer	regorafenib Resistant: C3 – Early Trials regorafenib Resistant : C3	regorafenib Resistant: C3 – Early Trials regorafenib Resistant : C3
MYC mutation	Diffuse Large B Cell Lymphoma	MYC mutation	Diffuse Large B Cell Lymphoma	CUDC-907 Sensitive: C3 – Early Trials CUDC-907 Sensitive : C3	CUDC-907 Sensitive: C3 – Early Trials CUDC-907 Sensitive : C3
MYC mutation	HER2 Positive Breast Cancer	MYC mutation	HER2 Positive Breast Cancer	trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials trastuzumab + atezolizumab + pertuzumab Resistant : C3	trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials trastuzumab + atezolizumab + pertuzumab Resistant : C3
MYC mutation	Triple Negative Breast Cancer	MYC mutation	Triple Negative Breast Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MYC mutation	Diffuse Large B Cell Lymphoma	MYC mutation	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3